Smartphone ECG for Heart Attack (STLEUISII Trial)

N/A

Recruiting

Research Sponsored by AliveCor

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Symptoms of chest pain upon presentation at the Emergency Department of the participating institution

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new device called AliveCor (AC) 12-lead (12L) ECG System that can record 4 leads of ECG at the same time and generate a

Who is the study for?

This trial is for adults over 18 who can consent to participate and are experiencing chest pain upon arrival at the Emergency Department. It's designed for those with various heart conditions, including heart failure, myocardial infarction (heart attack), and other related cardiovascular diseases.

What is being tested?

The trial is testing the AliveCor 12-lead ECG System, a new device that works with smartphones to record ECGs. The goal is to see if it can diagnose serious heart attacks (STEMI and NSTEMI) as accurately as standard ECG devices in hospitals.

What are the potential side effects?

Since this study involves non-invasive ECG monitoring using a smartphone-compatible device, there are no direct side effects from the intervention itself. However, participants may experience discomfort or anxiety during the ECG recording.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I experienced chest pain when I arrived at the emergency room.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: AliveCor 12-lead ECGExperimental Treatment1 Intervention

A single research-related procedure will be required (i.e., an AliveCor 12-lead ECG). Effort will be made to ensure that the performance of this procedure will not delay any treatment and/or diagnostic procedures that are part of usual or specialized care that the patient requires.

0 / 1Eligibility criteria met